



### **Jazz Pharmaceuticals Announcement Regarding Sunosi® (solriamfetol)**

Jazz Pharmaceuticals announced March 28, 2022 that the company has made the decision to transition Sunosi® (solriamfetol) into the care of Axsome Therapeutics.

Axsome is a growing, CNS-focused company, who Jazz believes displays the same patient-centric approach as Jazz and can support current and future patients who may benefit from Sunosi. Jazz believes this agreement will best support continuity of supply and access to Sunosi. Jazz will work with Axsome through this process to ensure the seamless transition for patients and customers.

Jazz and Axsome share an unwavering commitment to patient care and as such, we will work closely together throughout the transition period to ensure that the patient community will have uninterrupted access to Sunosi. The transition of Sunosi to Axsome's care will take effect after the deal closes.

Jazz is proud of the work the company has done to bring Sunosi to patients in need while raising awareness of the impact Excessive Daytime Sleepiness associated with narcolepsy or Obstructive Sleep Apnea has on people living with this debilitating condition. Jazz remains committed to leadership in sleep medicine and working alongside our advocacy partners to support patients who benefit from our current and future sleep and neuroscience medicines. Jazz remains committed to investing in sleep development programs and helping more patient with rare sleep disorders.

We thank you for your collaboration and cooperation in changing the lives of patients and look forward to continuing to work with you to support those living with serious sleep disorders.